Nadofaragene firadenovec, sold under the brand name adstiladrin, is a gene therapy for the treatment of bladder cancer It delivers a copy of the gene encoding ifnα2b to the bladder urothelium resulting in local expression of the ifnα2b protein for anti. Introduction on december 16, 2022, fda approved nadofaragene firadenovec (brand name adstiladrin), the first gene therapy for the treatment of bladder cancer
Natashanoel exclusive onlyfans leaked nudes
This medicine is to be used only by or under the direct supervision of a doctor.
